These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6
E. de Azambuja;  A P Holmes; M Piccart-Gebhart; E Holmes; S. Di Cosimo; R F Swaby; M Untch; C Jackisch; I Lang; I Smith; F Boyle; B Xu; C H Barrios; EA Perez; H A Azim Jr; S Kuemmel; C S Huang; P Vuylsteke; R K Hsieh; V Gorbunova; A Eniu; L Dreosti; N Tavartkiladze;  2014

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomized, open-label, multicentre, phase 3 trial and their association with pathological complete response

The Lancet Oncology,  Volume 15, Issue 10, Pages 1137-1146, doi:10.1016/S1470-2045(14)70320-1

M Scaltriti;  P Nuciforo; I Bradbury; J Sperinde; D Agbor-Tarh; C Campbell; A Chenna; J Winslow; V Serra; JL Parra; L Prudkin; J Jimenez; C Aura;  2015

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab

Clinical Cancer Research,  Volume 21, Issue 3, Pages 569-76, doi:10.1158/1078-0432.CCR-14-1824

CC O’Sulivan;  I Bradbury; C Campbell; M Spielmann; EA Perez; H Joensuu; JP Costantino; S Delaloge; P Rastogi; D Zardavas; KV Ballman; E Holmes; E. de Azambuja; M Piccart-Gebhart; JA Zujewski; RD Gelber;  2015

Efficiacy of Adjuvant Trastuzumab for Patients with Human Epidermal Growth Factor Receptor 2-Positive Early Breat Cancer and Tumors >2cm: A Meta-Analysis of the Randomized Trastuzumab Trials

Journal of Clinical Oncology,  Volume 33, Issue 24, Pages 2600-2608, doi:10.1200/JCO.2015.60.8620

R Salgado;  C Denkert; C Campbell; P Savas; P Nuciforo; C Aura; E. de Azambuja; H. Eidtmann; C Ellis; J Baselga; M Piccart-Gebhart; S Michiels; I Bradbury; C Sotiriou; S Loi;  2015

Tumor-Infiltrating Lymphocytes and Associations with Pathological Complet Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated with Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

JAMA Oncology,  Volume 1, Issue 4, Pages 448-454, doi:10.1001/jamaoncol.2015.0830

A Sonnenblick;  E. de Azambuja; D Agbor-Tarh; I Bradbury; C Campbell; Y Huang; AC Dueck; KI Pritchard; AC Wolff; C Jackisch; I Lang; M Untch; I Smith; F Boyle; B Xu; H Gomez; EA Perez; M. Piccart; H. A. Azim Jr;  2016

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial

Journal of the National Cancer Institute,  Volume 108, Issue 8, doi:10.1093/jnci/djw037

C. Criscitiello;  H. A. Azim Jr; D Agbor-Tarh; E. de Azambuja; M. Piccart; J Baselga; H. Eidtmann; S. Di Cosimo; I Bradbury; IT Rubio;  2013

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2- positive breast cancer: results from the NeoALTTO phase III trial

Annals of Oncology,  Volume 24, Issue No 8, Pages 1980-1985, doi:10.1093/annonc/mdt129

L. Zabaglo;  O. Stoss; J. Rüschoff; D. Zielinski; J Salter; M Arfi; I Bradbury; M Piccart-Gebhart; M Procter; M Dowsett;  2013

HER2 Staining Intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of Oncology,  Volume 24, Issue No 11, Pages 2761-2766, doi:10.1093/annonc/mdt275

1 2 3 4 5 6